Hemp-derived CBD companies increasingly face class-action claims by consumers and stockholders, driven by industry growth, product claims, regulatory uncertainties and preventable mistakes by the companies themselves. Michael Jones, partner in Goodwin’s Cannabis practice and author of a report detailing 13 class-action cases filed against publicly-held CBD and marijuana companies in 2019, discusses the issues behind the claims. Read the article in Hemp Industry Daily here.